Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists
journal contributionposted on 10.08.2006 by Alexander Pasternak, Dominick Marino, Pasquale P. Vicario, Julia Marie Ayala, Margaret A. Cascierri, William Parsons, Sander G. Mills, Malcolm MacCoss, Lihu Yang
Any type of content formally published in an academic journal, usually following a peer-review process.
Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an ongoing program targeting CCR2 antagonists. Optimization of 11 leading to antagonists 26 and 37 is described. Antagonist 26 was shown to have good oral bioavailability in rats. Antagonist 37 had a CCR2 IC50 of 59 nM and excellent potency in a functional assay measuring inhibition of MCP-1 induced monocyte chemotaxis (IC50 of 41 nM).